The supplied filings identify inomed Medizintechnik GmbH as applicant for two 510(k) submissions reviewed under the Neurology advisory committee. One covers a stereotactic instrument; the other covers electrical evoked-response stimulation devices and associated headboxes. Company-published product pages and brochures describe the SUSy stereotactic system and its components, while the ISIS products appear in the filing record by name. The collection is small and dated, so it describes these specific filings rather than the company's full portfolio or commercial position. [1][2][3][4]

SUSy stereotactic filing and documented components

K261157 covers the Stereotactic Ultralight System SUSy under product code HAW, regulation number 882.4560, device class 2, with a decision date of 6 November 2026 and a substantially equivalent decision. The submission was received 8 April 2026 and is listed as a Traditional clearance with a summary statement. The applicant address in the record is Im Hausgruen 29, 79312 Emmendingen, Germany; that is a filing address, not a verified headquarters. [1]

inomed's own SUSy brochure presents the system as a stereotactic platform organised around fixation, localisation and review, with a stereotactic arc, head ring holder, head fixing posts and OptiPins in multiple lengths. The brochure describes a head ring holder for solid adaptation to the operating table and a standardised starburst interface for skull clamps that enables AP mounting. The English product page refers to both a titanium and a ceramic head ring. [3][4]

The German-language brochure repeats the same component structure, naming Fixierung, Lokalisation and Überprüfung alongside the Zielbügel, Ringhalter and OptiPins. It describes the Ringhalter as a solid adaptation for the operating table and the standardised Starburst interface as enabling AP mounting. These are publisher descriptions of the product, not independently verified performance claims. [7]

ISIS stimulation and headbox filing

K263010 covers ISIS Headboxes, ISIS Neurostimulator, ISIS Xpert Plus, ISIS Xpert and ISIS Xpress under product code GWF, regulation number 882.1870, device class 2, with a decision date of 24 September 2026 and a substantially equivalent decision. The submission was received 28 August 2026 and is listed as a Special clearance with a summary statement. The FDA record describes the device category as Stimulator, Electrical, Evoked Response, with Neurology as the medical specialty. [2]

The FDA premarket notification page for K263010 repeats the applicant name and Emmendingen address, the 28 August 2026 receipt date, the 24 September 2026 decision date and the substantially equivalent decision. It lists the same five ISIS product names and the Neurology specialty. The page does not describe intended clinical use, hardware specifications or commercial availability. [5]

What the collection shows and what it does not

The supplied portfolio snapshot contains two linked records, both under the 510(k) pathway, and both carry a substantially equivalent decision. The smaller record sample also shows two substantially equivalent decisions. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio size or safety performance. [1][2]

Company-published pages place the SUSy system within functional neurosurgery and stereotaxy, and the FAQ page states that biopsy instruments and HF brain electrodes can be used on the MicroDrive. The company page mentions Wipfler and two long-term employees in connection with management, without further detail in the public information. No ownership structure, parent company or brand relationship is verified in these sources. [3][8][9]

The sources do not establish manufacturing sites, certifications, customer lists, pricing, clinical outcomes or first-hand testing. The FDA filing address should not be read as a headquarters designation, and the presence of a clearance does not by itself confirm commercial availability in any market. [1][2][5]